Real INBU feedback please!!!

Please someone/anyone provide REAL advice about a move to INBU in 2016:

good move? why or why not?

benefits?

current inflam pipeline?

expected salary/bonus?

Thanks to anyone trying to help someone make an informed career decision!

 

Same--and when are they looking to hire, have a couple irons in the fire, but would try to hold out for this.

 

-Depends on where you are currently, but good move overall. Supporting/Selling old drug for now.

Amgen Benefits are great. No question.

-Launches of Bone drug, Migraine/Neuro, and biosimilars in GI/Derm/Rheum over next 3 yrs

-base depends...90-120? bonus 35k

 

Romo is going to BCBU and Prolia will be given back to them as well. AMG 334 will be promoted to Neuro so Amgen will hire new reps with Neuro experience (like they did hiring CV reps for Repatha), not keep existing Enbrel reps. Biogen reps with CV reps will be the new AZ reps who got Repatha. INBU reps will launch Biosim if launch in 2017 but Abbvie will likely stall launch until 2020 in the courts. Biosim Humira will not need much support after launch. Read the facts before you drink the kool aid.

 

Thanks, I think working for Amgen would always be a great move just because of the benefits and recognition on a resume.

 

Any idea of hiring timeline?

 

Hiring timeline is half past the monkeys ass.

 

Some good info thanks. Also, if coming to INBU would they possibly move you to another salesforce based on pipeline fruition or keep selling Enbrel?

What are opportunities for advancement?

 

Quarter to his balls

 

Very few INBU reps were able to join the CV team. Unless it's a neph or rheum product, Amgen isn't moving you to a different sales force. They can hire reps in those areas with relationships cheaper than they can move you.

Advancement as a rep is limited. If you want to brown nose to be ACT level 3, then do so.

Being a DM is tough and best time is now as they are expanding neph. After that, it's going to be tough.

 

interesting...how much stability is there with INBU with biosims coming and nothing of note close in pipeline?

Also, how is management? Micromanagers or more laid back compared to big Pharma?

Inflam reps basically maintain Enbrel?

 

It's the question management is avoiding but reps want to know but are afraid to ask.

Amgen needs reps only to show that biosimilar is equivalent to the originator. Any REO thinks that creative messaging and campaigning will happen is delusional. Do you think rheums want to hear Humira data twice from the Humira rep and then the Amgen biosimilar rep?
Biosimilars are not innovative new drugs but generics for biologics. The only thing you need to prove is that your biosimilar is the same as the originator. You aren't doing new innovative trials. Many Amgen reps are too dumb to realize this and think its like launching Enbrel when it was new in 1998.

 

Each year Amgen becomes more and more big pharma and rules by metrics and fear

 

interesting...so not a bad move for salary increase, good benefits, biotech resume build or possible long term stability selling specialty vs pc Pharma

 

How many current INBU reps? Why are they hiring?

 

Amgen is nothing long term. I predict they will only have Neph business unit as long as AMG 416 is on patent. Enbrel and inflam will be support in a very limited manner after biosim launch as Enbrel share keeps eroding. By then, Enbrel derm share will be non-existant and rheum share will be significantly reduced.

If you are a PCP rep, Amgen may be an upgrade. If you are already specialty, Amgen would be a downgrade or equal at best.

 

to make your mom happy. It's a last ditch effort to up Enbrel sales. Call it a last hurrah

 

What should 10+ year PCP expect to ask for starting salary?